4 nominees · 7 ballot items.
The Oblong, Inc. proxy for the 2025 annual meeting presents seven proposals: (1) election of four directors; (2) amendment to the 2019 Equity Incentive Plan to increase the share reserve by 2,000,000 and add evergreen annual increases (5% per year 2026–2029) reflecting Oblong’s name change from Glowpoint, Inc. to Oblong, Inc.; (3) ratification of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025; (4) approval of the redomestication of Oblong, Inc. from Delaware to Nevada by conversion; (5) advisory vote on how frequently stockholders believe an advisory vote on executive compensation should be conducted; (6) advisory, non-binding approval of executive compensation; and (7) adjournment of the annual meeting to solicit additional proxies if necessary.
Elect four members of Oblong, Inc.’s Board of Directors to serve until the Company’s next annual meeting of stockholders, or until their respective successors are duly elected and qualified.
Increase the number of shares available for issuance by 2,000,000 and add provisions for annual increases (Evergreen Provision) for 2026–2029 at 5% of the shares outstanding on the preceding year; reflect the company’s name change from Glowpoint, Inc. to Oblong, Inc.; amendments reflected in Annex A.
Ratify EisnerAmper LLP as Oblong, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
Approve the redomestication of the Company from Delaware to Nevada by conversion and related Plan of Conversion, Nevada Charter, and Nevada Bylaws.
Stockholders may specify ONE YEAR, TWO YEARS, THREE YEARS, or ABSTAIN for how often the Say-on-Pay advisory vote should occur; the option with the most votes is the stockholders’ non-binding recommendation; the vote is advisory.
Say-on-Pay: advisory, non-binding approval of the compensation of Oblong’s named executive officers as disclosed in the Proxy Statement; the vote is non-binding.
Adjourn the annual meeting to solicit additional proxies if there are not sufficient votes in favor of proposals 1–4; the Board may adjourn as needed.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 83,060 | $131K |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1.7% | 59,400 | $94K |
| 3 | BOOTHBAY FUND MANAGEMENT, LLC | 1.4% | 46,700 | $74K |
| 4 | Virtu Financial LLC | 0.7% | 25,642 | $41K |
| 5 | VANGUARD FIDUCIARY TRUST CO | 0.5% | 18,472 | $29K |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 0.3% | 10,822 | $17K |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.3% | 8,927 | $14K |
| 8 | Allworth Financial LP | 0.0% | 8 | $13 |
| 9 | UBS Group AG | 0.0% | 5 | $8 |
| 10 | Axiom Investment Management LLC | 0.0% | 2 | $4 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.